Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor
February 19, 2021
Regor Therapeutics, a clinical-stage biotech company with operations in China and the US, has secured $90 million in a Series B round of financing led by the biomedical venture capital (VC) firm Lilly Asia Ventures (LAV).
The new round saw participation from investors including China-focused private equity (PE) firm Loyal Valley Capital (LVC); cross-border, pharmaceutical-focused PE Lanting Capital (LVC); TF Capital, which primarily invests in early-stage life sciences startups; and Vertex Ventures China.
Chinese drug maker Qilu Pharmaceutical Group had backed Regor’s Series A round.
Founded in July 2018, Regor specialises in the discovery and delivery of clinically differentiated, best- and first-in-class drugs for patients globally to treat cancer, immune disorders, and metabolic diseases.